ID   GALE_ECOLI              Reviewed;         338 AA.
AC   P09147; Q47493;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   15-MAR-2017, entry version 157.
DE   RecName: Full=UDP-glucose 4-epimerase;
DE            EC=5.1.3.2;
DE   AltName: Full=Galactowaldenase;
DE   AltName: Full=UDP-galactose 4-epimerase;
GN   Name=galE; Synonyms=galD; OrderedLocusNames=b0759, JW0742;
OS   Escherichia coli (strain K12).
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacterales;
OC   Enterobacteriaceae; Escherichia.
OX   NCBI_TaxID=83333;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3022232; DOI=10.1093/nar/14.19.7705;
RA   Lemaire H.-G., Mueller-Hill B.;
RT   "Nucleotide sequences of the gal E gene and the gal T gene of E.
RT   coli.";
RL   Nucleic Acids Res. 14:7705-7711(1986).
RN   [2]
RP   SEQUENCE REVISION.
RA   Lemaire H.-G.;
RL   Submitted (APR-1988) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=8905232; DOI=10.1093/dnares/3.3.137;
RA   Oshima T., Aiba H., Baba T., Fujita K., Hayashi K., Honjo A.,
RA   Ikemoto K., Inada T., Itoh T., Kajihara M., Kanai K., Kashimoto K.,
RA   Kimura S., Kitagawa M., Makino K., Masuda S., Miki T., Mizobuchi K.,
RA   Mori H., Motomura K., Nakamura Y., Nashimoto H., Nishio Y., Saito N.,
RA   Sampei G., Seki Y., Tagami H., Takemoto K., Wada C., Yamamoto Y.,
RA   Yano M., Horiuchi T.;
RT   "A 718-kb DNA sequence of the Escherichia coli K-12 genome
RT   corresponding to the 12.7-28.0 min region on the linkage map.";
RL   DNA Res. 3:137-155(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=9278503; DOI=10.1126/science.277.5331.1453;
RA   Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,
RA   Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F.,
RA   Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J.,
RA   Mau B., Shao Y.;
RT   "The complete genome sequence of Escherichia coli K-12.";
RL   Science 277:1453-1462(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=16738553; DOI=10.1038/msb4100049;
RA   Hayashi K., Morooka N., Yamamoto Y., Fujita K., Isono K., Choi S.,
RA   Ohtsubo E., Baba T., Wanner B.L., Mori H., Horiuchi T.;
RT   "Highly accurate genome sequences of Escherichia coli K-12 strains
RT   MG1655 and W3110.";
RL   Mol. Syst. Biol. 2:E1-E5(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-146.
RX   PubMed=2134186; DOI=10.3109/10425179009016043;
RA   Bernardi F., Bernardi A.;
RT   "Completed sequence of pKG1800, a vector for determination of
RT   transcription terminators.";
RL   DNA Seq. 1:147-150(1990).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-31.
RC   STRAIN=K12;
RX   PubMed=8564363;
RA   Walkenhorst H.M., Hemschemeier S.K., Eichenlaub R.;
RT   "Molecular analysis of the molybdate uptake operon, modABCD, of
RT   Escherichia coli and modR, a regulatory gene.";
RL   Microbiol. Res. 150:347-361(1995).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-6.
RX   PubMed=6301942; DOI=10.1016/0378-1119(83)90154-3;
RA   Busby S., Dreyfus M.;
RT   "Segment-specific mutagenesis of the regulatory region in the
RT   Escherichia coli galactose operon: isolation of mutations reducing the
RT   initiation of transcription and translation.";
RL   Gene 21:121-131(1983).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   INDUCTION.
RX   PubMed=14235524;
RA   Wilson D.B., Hogness D.S.;
RT   "The enzymes of the galactose operon in Escherichia coli. I.
RT   Purification and characterization of uridine diphosphogalactose 4-
RT   epimerase.";
RL   J. Biol. Chem. 239:2469-2481(1964).
RN   [10]
RP   SUBUNIT.
RX   PubMed=4305667;
RA   Wilson D.B., Hogness D.S.;
RT   "The enzymes of the galactose operon in Escherichia coli. II. The
RT   subunits of uridine diphosphogalactose 4-epimerase.";
RL   J. Biol. Chem. 244:2132-2136(1969).
RN   [11]
RP   MUTAGENESIS OF LYS-153, BIOPHYSICOCHEMICAL PROPERTIES, AND COFACTOR.
RX   PubMed=8241178; DOI=10.1021/bi00211a035;
RA   Swanson B.A., Frey P.A.;
RT   "Identification of lysine 153 as a functionally important residue in
RT   UDP-galactose 4-epimerase from Escherichia coli.";
RL   Biochemistry 32:13231-13236(1993).
RN   [12]
RP   COFACTOR, AND SUBUNIT.
RX   PubMed=8652544; DOI=10.1021/bi960102v;
RA   Liu Y., Vanhooke J.L., Frey P.A.;
RT   "UDP-galactose 4-epimerase: NAD+ content and a charge-transfer band
RT   associated with the substrate-induced conformational transition.";
RL   Biochemistry 35:7615-7620(1996).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) IN COMPLEX WITH NAD AND
RP   SUSBTRATE ANALOGS, ENZYME REGULATION, AND SUBUNIT.
RX   PubMed=1579570; DOI=10.1002/prot.340120409;
RA   Bauer A.J., Rayment I., Frey P.A., Holden H.M.;
RT   "The molecular structure of UDP-galactose 4-epimerase from Escherichia
RT   coli determined at 2.5-A resolution.";
RL   Proteins 12:372-381(1992).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) IN COMPLEX WITH NAD AND
RP   SUBSTRATE ANALOGS, AND COFACTOR.
RX   PubMed=8611559; DOI=10.1021/bi952715y;
RA   Thoden J.B., Frey P.A., Holden H.M.;
RT   "Crystal structures of the oxidized and reduced forms of UDP-galactose
RT   4-epimerase isolated from Escherichia coli.";
RL   Biochemistry 35:2557-2566(1996).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) IN COMPLEX WITH NAD AND
RP   SUBSTRATE ANALOGS, ACTIVE SITE, AND COFACTOR.
RX   PubMed=8611497; DOI=10.1021/bi9601114;
RA   Thoden J.B., Frey P.A., Holden H.M.;
RT   "Molecular structure of the NADH/UDP-glucose abortive complex of UDP-
RT   galactose 4-epimerase from Escherichia coli: implications for the
RT   catalytic mechanism.";
RL   Biochemistry 35:5137-5144(1996).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) IN COMPLEX WITH NAD AND
RP   SUBSTRATE ANALOGS, COFACTOR, AND SUBUNIT.
RX   PubMed=8931134; DOI=10.1002/pro.5560051102;
RA   Thoden J.B., Frey P.A., Holden H.M.;
RT   "High-resolution X-ray structure of UDP-galactose 4-epimerase
RT   complexed with UDP-phenol.";
RL   Protein Sci. 5:2149-2161(1996).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) IN COMPLEX WITH NAD AND
RP   SUBSTRATE ANALOGS, AND COFACTOR.
RX   PubMed=9174344; DOI=10.1021/bi970025j;
RA   Thoden J.B., Hegeman A.D., Wesenberg G., Chapeau M.C., Frey P.A.,
RA   Holden H.M.;
RT   "Structural analysis of UDP-sugar binding to UDP-galactose 4-epimerase
RT   from Escherichia coli.";
RL   Biochemistry 36:6294-6304(1997).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF MUTANT PHE-149 IN COMPLEX
RP   WITH SUBSTRATE ANALOGS AND NAD, MUTAGENESIS OF SER-124 AND TYR-149,
RP   BIOPHYSICOCHEMICAL PROPERTIES, REACTION MECHANISM, AND ENZYME
RP   REGULATION.
RX   PubMed=9271498; DOI=10.1021/bi970430a;
RA   Liu Y., Thoden J.B., Kim J., Berger E., Gulick A.M., Ruzicka F.J.,
RA   Holden H.M., Frey P.A.;
RT   "Mechanistic roles of tyrosine 149 and serine 124 in UDP-galactose 4-
RT   epimerase from Escherichia coli.";
RL   Biochemistry 36:10675-10684(1997).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF MUTANTS ALA-124; THR-124 AND
RP   VAL-124 IN COMPLEX WITH SUBSTRATE ANALOGS AND NAD, AND MUTAGENESIS OF
RP   SER-124.
RX   PubMed=9271499; DOI=10.1021/bi9704313;
RA   Thoden J.B., Gulick A.M., Holden H.M.;
RT   "Molecular structures of the S124A, S124T, and S124V site-directed
RT   mutants of UDP-galactose 4-epimerase from Escherichia coli.";
RL   Biochemistry 36:10685-10695(1997).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF DOUBLE MUTANT ALA-124/PHE-149
RP   IN COMPLEX WITH SUBSTRATE ANALOGS AND NAD, MUTAGENESIS OF SER-124 AND
RP   TYR-149, REACTION MECHANISM, AND COFACTOR.
RX   PubMed=9708982; DOI=10.1021/bi9808969;
RA   Thoden J.B., Holden H.M.;
RT   "Dramatic differences in the binding of UDP-galactose and UDP-glucose
RT   to UDP-galactose 4-epimerase from Escherichia coli.";
RL   Biochemistry 37:11469-11477(1998).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF MUTANT CYS-299 IN COMPLEX
RP   WITH SUBSTRATE ANALOGS AND NAD, MUTAGENESIS OF TYR-299, SUBSTRATE
RP   SPECIFICITY, AND COFACTOR.
RX   PubMed=12019271; DOI=10.1074/jbc.M204413200;
RA   Thoden J.B., Henderson J.M., Fridovich-Keil J.L., Holden H.M.;
RT   "Structural analysis of the Y299C mutant of Escherichia coli UDP-
RT   galactose 4-epimerase. Teaching an old dog new tricks.";
RL   J. Biol. Chem. 277:27528-27534(2002).
CC   -!- FUNCTION: Involved in the metabolism of galactose. Catalyzes the
CC       conversion of UDP-galactose (UDP-Gal) to UDP-glucose (UDP-Glc)
CC       through a mechanism involving the transient reduction of NAD. It
CC       is only active on UDP-galactose and UDP-glucose.
CC       {ECO:0000269|PubMed:14235524}.
CC   -!- CATALYTIC ACTIVITY: UDP-alpha-D-glucose = UDP-alpha-D-galactose.
CC       {ECO:0000269|PubMed:14235524}.
CC   -!- COFACTOR:
CC       Name=NAD(+); Xref=ChEBI:CHEBI:57540;
CC         Evidence={ECO:0000269|PubMed:12019271,
CC         ECO:0000269|PubMed:8241178, ECO:0000269|PubMed:8611497,
CC         ECO:0000269|PubMed:8611559, ECO:0000269|PubMed:8652544,
CC         ECO:0000269|PubMed:8931134, ECO:0000269|PubMed:9174344,
CC         ECO:0000269|PubMed:9708982};
CC   -!- ENZYME REGULATION: Inhibited by UDP-phenol and NaBH3CN.
CC       {ECO:0000269|PubMed:1579570, ECO:0000269|PubMed:9271498}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=18 uM for UDP-Gal (at pH 8.5) {ECO:0000269|PubMed:14235524,
CC         ECO:0000269|PubMed:8241178, ECO:0000269|PubMed:9271498};
CC         KM=160 uM for UDP-Gal (at pH 8.5 and 27 degrees Celsius)
CC         {ECO:0000269|PubMed:14235524, ECO:0000269|PubMed:8241178,
CC         ECO:0000269|PubMed:9271498};
CC         KM=225 uM for UDP-Glc (at pH 8.5 and 27 degrees Celsius)
CC         {ECO:0000269|PubMed:14235524, ECO:0000269|PubMed:8241178,
CC         ECO:0000269|PubMed:9271498};
CC         Note=Kcat is 760 sec(-1) for UDP-Glc (at pH 8.5 and 27 degrees
CC         Celsius) and 24 sec(-1) for UDP-Gal (at pH 8.5).;
CC   -!- PATHWAY: Carbohydrate metabolism; galactose metabolism.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:12019271,
CC       ECO:0000269|PubMed:1579570, ECO:0000269|PubMed:4305667,
CC       ECO:0000269|PubMed:8611497, ECO:0000269|PubMed:8611559,
CC       ECO:0000269|PubMed:8652544, ECO:0000269|PubMed:8931134,
CC       ECO:0000269|PubMed:9174344, ECO:0000269|PubMed:9271498,
CC       ECO:0000269|PubMed:9271499, ECO:0000269|PubMed:9708982}.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-909010, EBI-909010;
CC       P39409:yjjW; NbExp=2; IntAct=EBI-909010, EBI-9132384;
CC   -!- INDUCTION: By D-galactose and D-fucose.
CC       {ECO:0000269|PubMed:14235524}.
CC   -!- SIMILARITY: Belongs to the NAD(P)-dependent epimerase/dehydratase
CC       family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X06226; CAA29573.1; -; Genomic_DNA.
DR   EMBL; U00096; AAC73846.1; -; Genomic_DNA.
DR   EMBL; AP009048; BAA35421.1; -; Genomic_DNA.
DR   EMBL; X51449; CAA35813.1; -; Genomic_DNA.
DR   EMBL; U07867; AAB06890.1; -; Genomic_DNA.
DR   EMBL; J01613; AAA87978.1; -; Genomic_DNA.
DR   PIR; S02089; XUECUG.
DR   RefSeq; NP_415280.3; NC_000913.3.
DR   RefSeq; WP_001265438.1; NZ_LN832404.1.
DR   PDB; 1A9Y; X-ray; 1.80 A; A=1-338.
DR   PDB; 1A9Z; X-ray; 1.90 A; A=1-338.
DR   PDB; 1KVQ; X-ray; 2.15 A; A=1-338.
DR   PDB; 1KVR; X-ray; 1.90 A; A=1-338.
DR   PDB; 1KVS; X-ray; 2.15 A; A=1-338.
DR   PDB; 1KVT; X-ray; 2.15 A; A=1-338.
DR   PDB; 1KVU; X-ray; 1.90 A; A=1-338.
DR   PDB; 1LRJ; X-ray; 1.90 A; A=1-338.
DR   PDB; 1LRK; X-ray; 1.75 A; A=1-338.
DR   PDB; 1LRL; X-ray; 1.80 A; A=1-338.
DR   PDB; 1NAH; X-ray; 1.80 A; A=1-338.
DR   PDB; 1NAI; X-ray; 2.00 A; A=1-338.
DR   PDB; 1UDA; X-ray; 1.80 A; A=1-338.
DR   PDB; 1UDB; X-ray; 1.65 A; A=1-338.
DR   PDB; 1UDC; X-ray; 1.65 A; A=1-338.
DR   PDB; 1XEL; X-ray; 1.80 A; A=1-338.
DR   PDB; 2UDP; X-ray; 1.80 A; A/B=1-338.
DR   PDB; 5GY7; X-ray; 1.43 A; A/B=1-338.
DR   PDBsum; 1A9Y; -.
DR   PDBsum; 1A9Z; -.
DR   PDBsum; 1KVQ; -.
DR   PDBsum; 1KVR; -.
DR   PDBsum; 1KVS; -.
DR   PDBsum; 1KVT; -.
DR   PDBsum; 1KVU; -.
DR   PDBsum; 1LRJ; -.
DR   PDBsum; 1LRK; -.
DR   PDBsum; 1LRL; -.
DR   PDBsum; 1NAH; -.
DR   PDBsum; 1NAI; -.
DR   PDBsum; 1UDA; -.
DR   PDBsum; 1UDB; -.
DR   PDBsum; 1UDC; -.
DR   PDBsum; 1XEL; -.
DR   PDBsum; 2UDP; -.
DR   PDBsum; 5GY7; -.
DR   ProteinModelPortal; P09147; -.
DR   SMR; P09147; -.
DR   BioGrid; 4261900; 143.
DR   DIP; DIP-9728N; -.
DR   IntAct; P09147; 15.
DR   STRING; 511145.b0759; -.
DR   DrugBank; DB02790; Phenyl-Uridine-5'-Diphosphate.
DR   DrugBank; DB01861; Uridine diphosphate glucose.
DR   DrugBank; DB03435; Uridine-5'-Diphosphate.
DR   DrugBank; DB04097; Uridine-5'-Diphosphate-4-Deoxy-4-Fluoro-Alpha-D-Galactose.
DR   DrugBank; DB02421; Uridine-5'-Diphosphate-Mannose.
DR   DrugBank; DB03397; Uridine-Diphosphate-N-Acetylglucosamine.
DR   SWISS-2DPAGE; P09147; -.
DR   EPD; P09147; -.
DR   PaxDb; P09147; -.
DR   PRIDE; P09147; -.
DR   EnsemblBacteria; AAC73846; AAC73846; b0759.
DR   EnsemblBacteria; BAA35421; BAA35421; BAA35421.
DR   GeneID; 945354; -.
DR   KEGG; ecj:JW0742; -.
DR   KEGG; eco:b0759; -.
DR   PATRIC; 32116719; VBIEscCol129921_0785.
DR   EchoBASE; EB0357; -.
DR   EcoGene; EG10362; galE.
DR   eggNOG; ENOG4105CMR; Bacteria.
DR   eggNOG; COG1087; LUCA.
DR   HOGENOM; HOG000168001; -.
DR   InParanoid; P09147; -.
DR   KO; K01784; -.
DR   OMA; CGCKVYN; -.
DR   PhylomeDB; P09147; -.
DR   BioCyc; EcoCyc:UDPGLUCEPIM-MONOMER; -.
DR   BioCyc; MetaCyc:UDPGLUCEPIM-MONOMER; -.
DR   BRENDA; 5.1.3.2; 2026.
DR   SABIO-RK; P09147; -.
DR   UniPathway; UPA00214; -.
DR   EvolutionaryTrace; P09147; -.
DR   PRO; PR:P09147; -.
DR   Proteomes; UP000000318; Chromosome.
DR   Proteomes; UP000000625; Chromosome.
DR   GO; GO:0005737; C:cytoplasm; IDA:EcoliWiki.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0070403; F:NAD+ binding; IDA:EcoCyc.
DR   GO; GO:0016857; F:racemase and epimerase activity, acting on carbohydrates and derivatives; IDA:EcoliWiki.
DR   GO; GO:0003978; F:UDP-glucose 4-epimerase activity; IDA:EcoCyc.
DR   GO; GO:0005975; P:carbohydrate metabolic process; IMP:EcoliWiki.
DR   GO; GO:0009242; P:colanic acid biosynthetic process; IMP:EcoCyc.
DR   GO; GO:0033499; P:galactose catabolic process via UDP-galactose; IMP:EcoCyc.
DR   GO; GO:0006012; P:galactose metabolic process; IDA:EcoliWiki.
DR   CDD; cd05247; UDP_G4E_1_SDR_e; 1.
DR   Gene3D; 3.40.50.720; -; 1.
DR   InterPro; IPR016040; NAD(P)-bd_dom.
DR   InterPro; IPR005886; UDP_G4E.
DR   Pfam; PF16363; GDP_Man_Dehyd; 1.
DR   SUPFAM; SSF51735; SSF51735; 1.
DR   TIGRFAMs; TIGR01179; galE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Carbohydrate metabolism; Complete proteome;
KW   Galactose metabolism; Isomerase; NAD; Reference proteome.
FT   CHAIN         1    338       UDP-glucose 4-epimerase.
FT                                /FTId=PRO_0000183203.
FT   NP_BIND      11     12       NAD. {ECO:0000269|PubMed:12019271,
FT                                ECO:0000269|PubMed:1579570,
FT                                ECO:0000269|PubMed:8611497,
FT                                ECO:0000269|PubMed:8611559,
FT                                ECO:0000269|PubMed:8931134,
FT                                ECO:0000269|PubMed:9174344,
FT                                ECO:0000269|PubMed:9271498,
FT                                ECO:0000269|PubMed:9271499,
FT                                ECO:0000269|PubMed:9708982}.
FT   NP_BIND      31     36       NAD. {ECO:0000269|PubMed:12019271,
FT                                ECO:0000269|PubMed:1579570,
FT                                ECO:0000269|PubMed:8611497,
FT                                ECO:0000269|PubMed:8611559,
FT                                ECO:0000269|PubMed:8931134,
FT                                ECO:0000269|PubMed:9174344,
FT                                ECO:0000269|PubMed:9271498,
FT                                ECO:0000269|PubMed:9271499,
FT                                ECO:0000269|PubMed:9708982}.
FT   NP_BIND      58     59       NAD. {ECO:0000269|PubMed:12019271,
FT                                ECO:0000269|PubMed:1579570,
FT                                ECO:0000269|PubMed:8611497,
FT                                ECO:0000269|PubMed:8611559,
FT                                ECO:0000269|PubMed:8931134,
FT                                ECO:0000269|PubMed:9174344,
FT                                ECO:0000269|PubMed:9271498,
FT                                ECO:0000269|PubMed:9271499,
FT                                ECO:0000269|PubMed:9708982}.
FT   NP_BIND      80     84       NAD. {ECO:0000269|PubMed:12019271,
FT                                ECO:0000269|PubMed:1579570,
FT                                ECO:0000269|PubMed:8611497,
FT                                ECO:0000269|PubMed:8611559,
FT                                ECO:0000269|PubMed:8931134,
FT                                ECO:0000269|PubMed:9174344,
FT                                ECO:0000269|PubMed:9271498,
FT                                ECO:0000269|PubMed:9271499,
FT                                ECO:0000269|PubMed:9708982}.
FT   REGION      199    200       Substrate binding.
FT   REGION      216    218       Substrate binding.
FT   REGION      292    295       Substrate binding.
FT   ACT_SITE    149    149       Proton acceptor.
FT                                {ECO:0000269|PubMed:8611497}.
FT   BINDING      99     99       NAD. {ECO:0000269|PubMed:12019271,
FT                                ECO:0000269|PubMed:1579570,
FT                                ECO:0000269|PubMed:8611497,
FT                                ECO:0000269|PubMed:8611559,
FT                                ECO:0000269|PubMed:8931134,
FT                                ECO:0000269|PubMed:9174344,
FT                                ECO:0000269|PubMed:9271498,
FT                                ECO:0000269|PubMed:9271499,
FT                                ECO:0000269|PubMed:9708982}.
FT   BINDING     124    124       NAD. {ECO:0000269|PubMed:12019271,
FT                                ECO:0000269|PubMed:1579570,
FT                                ECO:0000269|PubMed:8611497,
FT                                ECO:0000269|PubMed:8611559,
FT                                ECO:0000269|PubMed:8931134,
FT                                ECO:0000269|PubMed:9174344,
FT                                ECO:0000269|PubMed:9271498,
FT                                ECO:0000269|PubMed:9271499,
FT                                ECO:0000269|PubMed:9708982}.
FT   BINDING     124    124       Substrate.
FT   BINDING     149    149       NAD. {ECO:0000269|PubMed:12019271,
FT                                ECO:0000269|PubMed:1579570,
FT                                ECO:0000269|PubMed:8611497,
FT                                ECO:0000269|PubMed:8611559,
FT                                ECO:0000269|PubMed:8931134,
FT                                ECO:0000269|PubMed:9174344,
FT                                ECO:0000269|PubMed:9271498,
FT                                ECO:0000269|PubMed:9271499,
FT                                ECO:0000269|PubMed:9708982}.
FT   BINDING     149    149       Substrate.
FT   BINDING     153    153       NAD. {ECO:0000269|PubMed:12019271,
FT                                ECO:0000269|PubMed:1579570,
FT                                ECO:0000269|PubMed:8611497,
FT                                ECO:0000269|PubMed:8611559,
FT                                ECO:0000269|PubMed:8931134,
FT                                ECO:0000269|PubMed:9174344,
FT                                ECO:0000269|PubMed:9271498,
FT                                ECO:0000269|PubMed:9271499,
FT                                ECO:0000269|PubMed:9708982}.
FT   BINDING     178    178       NAD; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:12019271,
FT                                ECO:0000269|PubMed:1579570,
FT                                ECO:0000269|PubMed:8611497,
FT                                ECO:0000269|PubMed:8611559,
FT                                ECO:0000269|PubMed:8931134,
FT                                ECO:0000269|PubMed:9174344,
FT                                ECO:0000269|PubMed:9271498,
FT                                ECO:0000269|PubMed:9271499,
FT                                ECO:0000269|PubMed:9708982}.
FT   BINDING     179    179       Substrate.
FT   BINDING     231    231       Substrate.
FT   BINDING     299    299       Substrate.
FT   MUTAGEN     124    124       S->A: No major structural changes.
FT                                Catalytic efficiency is very low and
FT                                affinity binding is 21% of the wild-type
FT                                enzyme. {ECO:0000269|PubMed:9271498,
FT                                ECO:0000269|PubMed:9271499,
FT                                ECO:0000269|PubMed:9708982}.
FT   MUTAGEN     124    124       S->T: No major structural changes.
FT                                Catalytic efficiency is about 30% of that
FT                                of the wild-type enzyme, and affinity
FT                                binding is similar to that of the native
FT                                enzyme. {ECO:0000269|PubMed:9271498,
FT                                ECO:0000269|PubMed:9271499,
FT                                ECO:0000269|PubMed:9708982}.
FT   MUTAGEN     149    149       Y->F: No major structural changes.
FT                                Catalytic efficiency is very low and
FT                                affinity binding is 12% of the wild-type
FT                                enzyme. {ECO:0000269|PubMed:9271498,
FT                                ECO:0000269|PubMed:9708982}.
FT   MUTAGEN     153    153       K->A: Decreases the catalytic activity.
FT                                Not reduced by sugars in the presence or
FT                                absence of UMP. It contains very little
FT                                NADH. {ECO:0000269|PubMed:8241178}.
FT   MUTAGEN     153    153       K->M: Decreases the catalytic activity.
FT                                Not reduced by sugars in the presence or
FT                                absence of UMP. It contains very little
FT                                NADH. {ECO:0000269|PubMed:8241178}.
FT   MUTAGEN     299    299       Y->C: Loss of epimerase activity with
FT                                UDP-Gal by almost 5-fold, but it results
FT                                in a gain of epimerase activity with
FT                                uridine diphosphate N-acetylglucosamine
FT                                (UDP-GlcNAc) by 230-fold with minimal
FT                                changes in its three-dimensional
FT                                structure. {ECO:0000269|PubMed:12019271}.
FT   CONFLICT    140    145       FPTGTP -> LLPIPG (in Ref. 6; CAA35813).
FT                                {ECO:0000305}.
FT   STRAND        2      6       {ECO:0000244|PDB:5GY7}.
FT   TURN          7      9       {ECO:0000244|PDB:5GY7}.
FT   HELIX        11     22       {ECO:0000244|PDB:5GY7}.
FT   STRAND       26     31       {ECO:0000244|PDB:5GY7}.
FT   STRAND       34     36       {ECO:0000244|PDB:5GY7}.
FT   HELIX        38     40       {ECO:0000244|PDB:5GY7}.
FT   HELIX        41     48       {ECO:0000244|PDB:5GY7}.
FT   STRAND       53     56       {ECO:0000244|PDB:5GY7}.
FT   HELIX        62     71       {ECO:0000244|PDB:5GY7}.
FT   STRAND       75     79       {ECO:0000244|PDB:5GY7}.
FT   HELIX        86     91       {ECO:0000244|PDB:5GY7}.
FT   HELIX        93    114       {ECO:0000244|PDB:5GY7}.
FT   STRAND      118    124       {ECO:0000244|PDB:5GY7}.
FT   HELIX       125    128       {ECO:0000244|PDB:5GY7}.
FT   STRAND      134    136       {ECO:0000244|PDB:5GY7}.
FT   HELIX       148    166       {ECO:0000244|PDB:5GY7}.
FT   STRAND      171    177       {ECO:0000244|PDB:5GY7}.
FT   STRAND      179    181       {ECO:0000244|PDB:5GY7}.
FT   STRAND      187    189       {ECO:0000244|PDB:5GY7}.
FT   STRAND      194    196       {ECO:0000244|PDB:5GY7}.
FT   HELIX       200    208       {ECO:0000244|PDB:5GY7}.
FT   STRAND      211    213       {ECO:0000244|PDB:5GY7}.
FT   STRAND      215    218       {ECO:0000244|PDB:5GY7}.
FT   STRAND      222    224       {ECO:0000244|PDB:5GY7}.
FT   STRAND      233    235       {ECO:0000244|PDB:5GY7}.
FT   HELIX       236    250       {ECO:0000244|PDB:5GY7}.
FT   STRAND      255    262       {ECO:0000244|PDB:5GY7}.
FT   HELIX       269    280       {ECO:0000244|PDB:5GY7}.
FT   STRAND      286    289       {ECO:0000244|PDB:5GY7}.
FT   HELIX       304    310       {ECO:0000244|PDB:5GY7}.
FT   HELIX       318    331       {ECO:0000244|PDB:5GY7}.
SQ   SEQUENCE   338 AA;  37265 MW;  5CA8B4F7903F7792 CRC64;
     MRVLVTGGSG YIGSHTCVQL LQNGHDVIIL DNLCNSKRSV LPVIERLGGK HPTFVEGDIR
     NEALMTEILH DHAIDTVIHF AGLKAVGESV QKPLEYYDNN VNGTLRLISA MRAANVKNFI
     FSSSATVYGD QPKIPYVESF PTGTPQSPYG KSKLMVEQIL TDLQKAQPDW SIALLRYFNP
     VGAHPSGDMG EDPQGIPNNL MPYIAQVAVG RRDSLAIFGN DYPTEDGTGV RDYIHVMDLA
     DGHVVAMEKL ANKPGVHIYN LGAGVGNSVL DVVNAFSKAC GKPVNYHFAP RREGDLPAYW
     ADASKADREL NWRVTRTLDE MAQDTWHWQS RHPQGYPD
//
